

Supplementary Fig. S1. Comparison of plasma ozoralizumab concentrations in patients with seropositive and seronegative RA.

Plasma concentration–time profiles from the first dose to 4 weeks (A, B) and trough concentrations throughout 52 weeks (C, D) with methotrexate are shown. Seropositive RA indicates an anti–cyclic citrullinated peptide antibody level ≥ 4.5 U/mL and/or rheumatoid factor level > 15 IU/mL. RA rheumatoid arthritis, SD standard deviation.

OHZORA trial

